Montreal, Toronto, Vancouver (June 6, 2023) – adMare BioInnovations, a leader in the Canadian life sciences sector, is pleased to announce the launch of the adMare Institute, a new voice aimed at advancing the life sciences and related public policy in Canada. The announcement was made today at the prestigious BIO International Conference in Boston.
Read MoreMONTREAL, June 5, 2023 /PRNewswire/ - Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.
Read MoreGrant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.
MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.
Read Morecreation and exchange of innovative ideas.
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal. Located in the iconic Place Gare Viger, the office has been designed to provide a modern workplace that meets the needs of Novartis' associates and facilitates closer collaboration with key stakeholders.
Read MorePfizer Canada ULC announces the launch of its Healthcare Hub, an initiative with Canadian tech and innovation startups to scale up health solutions, with the goal of enhancing outcomes and the patient experience in important areas of need in Canadian healthcare.
Read MoreenGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.
Read MoreThe Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph through a partnership with OmniaBio Inc., CCRM and the university. The training program, to begin in summer 2023, will cater to recent post-secondary graduates, industry professionals and companies growing their roster of clean room manufacturing staff. The fast growth of cell and gene therapies (CGTs) has made it a challenge for the global industry to keep up with talent requirements. This new CGT technical training site will begin to address the industry's critical training needs and represents the first stage of a larger, multi-site training strategy for CATTI.
Read MoreBIOQuébec: a powerful facilitator for your organization
When Anie Perrault, then executive director, met Frédéric Leduc for the first time in 2014, she convinced him to become a member by highlighting the benefits of a strong, extensive network and the possibility of makinghis voice heard via BIOQuébec. Frédéric immediately seized this unique opportunity to meet potential clients and collaborators for the young biotech he had co-founded.
Read MoreAs a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.
Read MoreBausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray).
RYALTRIS has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Read MoreAs part of the Effervescence conference, the Centre Québécois d'Innovation en Biotechnologie (CQIB) announced a contribution of $420,000 to seven startups for the clinical data validation of new medical technologies.
Read MoreMcGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.
Read MorePharma in silica inc. announces today the closing of a $ 2,000,000 funding to continue the development of OpPacli™, an original nanomedicine developed to provide patients suffering from certain solid cancers with a well-tolerated and more efficient chemotherapy.
Read MoreWe are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.
Read MoreadMare BioInnovations is pleased to announce it has achieved LEED® v4 certification for the conception and construction of Building 2 at the Montreal Innovation Centre. LEED (Leadership in Energy and Environmental Design) was developed by the U.S. Green Building Council (USGBC) and is administered in Canada by the Canada Green Building Council (CAGBC). LEED is the most widely used green building rating system in the world and an international symbol of excellence. Through design, construction, and operation practices that improve environmental and human health, LEED-certified buildings are helping to make the world more sustainable.
Read MoreCQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie et de l’Innovation et de l’Énergie (MEIE). This funding, combined with the support of the Quebec company Feldan Therapeutics and the biotech company Amgen, will support the development of new therapeutic options. This project is part of a larger collaboration between the two companies, worth $1,427,757, to expand the potential of Feldan’s unique drug delivery technology.
Read MoreThe Ontario government is investing $7.5 million to help build a state-of-the-art Innovation Arena at the University of Waterloo. The new $35 million facility will be a hub for innovation in Ontario’s life sciences sector in Kitchener and Waterloo, supporting the development of new health technology and the commercialization of intellectual property and encouraging investment and job creation.
Read MoreA new made-in-B.C. Life Sciences and Biomanufacturing Strategy outlines how the Province will capitalize on the industry value chain from discovery through to clinical trials and manufacturing by supporting targeted investments in people and infrastructure. To help grow innovative local companies, the Province is investing $10 million in a new wet lab facility with adMare Bioinnovations.
Read MoreLaval, Canada – (BUSINESSWIRE) – April 13, 2023 – BIOQuébec, CQDM, Fonds de solidarité FTQ and adMare BioInnovations, co-organizers of Sweet Biopharma Day, are pleased to announce that Epitopea, represented by Steven Klein, is the winner of the 2023 edition.
Read MoreThe adMare Academy is proud to launch the BioInnovation Scientist (BIS) Program: Foundations. This online, cohort-based program will provide early-career scientists with fundamental knowledge in therapeutics development while simultaneously building their professional skills to succeed in the Canadian life sciences industry.
Read More